GuNA-modified antisense gapmers show prolonged activity in mouse brain
Academic source · Nucleic Acid Therapeutics / PubMed
Source published: · Event / reporting date: 2026-10-29
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What the paper reports
Based on the PubMed abstract, researchers combined guanidine-bridged nucleic acid and MOE modifications in antisense gapmers, reporting improved knockdown in laboratory and animal experiments. Activity persisted beyond 24 weeks in mouse brain after intracerebroventricular administration. The study also examined immune responses and toxicity; these preclinical results do not establish human safety or efficacy.
Why this paper is included
Analysis: Chemical modification may improve CNS ASO durability, but invasive administration, translational safety, and human dose requirements remain important development questions.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections